Idh-Mutant Tumors

Ivosidenib or enasidenib in combination with chemotherapy showed promising safety and efficacy profiles for newly diagnosed IDH-mutated acute myeloid leukemia, according to a phase 1 trial presented at ASH Annual Meeting and Exposition.

In this video, Alexander Edward Perl, MD, MS, spoke with Healio about a study assessing the potential benefit of ceasing venetoclax-based therapy after remission in patients with acute myeloid leukemia.

Olaparib monotherapy appeared well-tolerated and demonstrated evidence of antitumor activity among patients with heavily pretreated isocitrate dehydrogenase-mutant high-grade glioma, according to results of the phase 2 OLAGLI study.

Low-grade glioma is a historically challenging cancer to treat, with some patients succumbing to the disease within weeks of diagnosis and others surviving for decades.

Adults with acute myeloid leukemia with IDH mutations appeared to be at increased risk for coronary artery disease and exacerbated cardiotoxicity during treatment with anthracyclines, according to study results.